SuperworthMarker Therapeutics MRKR
- Market cap
- $16M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Marker Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $257.6K−74% | $1.1M+39% | $1.2M+1% | $1.2M+53% | $1.9M+648% | $2.3M+113% | $349.1K−72% | $861.2K−26% | $1.2M−36% | $1.1M−51% | n/a | n/a | |
| R&D | $2M−43% | $2.6M−50% | $2.6M−24% | $2.3M−2% | $3.5M+70% | $5.1M+94% | $3.1M+22% | $4.2M+79% | $2.3M−32% | $2.1M−58% | $2.8M−9% | $1.5M−65% |
| SG&A | $1.4M−56% | $1.4M−15% | $1.2M−44% | $1.1M−55% | $854.7K−40% | $1M−25% | $1.4M+12% | $945.2K−17% | $1M+20% | $846.6K−18% | $1.2M−10% | $1.1M+21% |
| −$3.2M−45% | −$2.9M−24% | −$2.5M−41% | −$2.3M−44% | −$2.4M−25% | −$3.9M+31% | −$5M+95% | −$5.1M+122% | −$2.1M−11% | −$1.9M−51% | −$4.1M−18% | −$2.6M−49% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$3M−57% | −$2.8M−27% | −$2.4M−52% | −$2.2M | −$2.3M−23% | −$3.8M+37% | −$4.4M+86% | −$4M+83% | −$2M−13% | −$1.7M−56% | −$3.2M−29% | −$1.8M−55% |
| −$0.34−59% | −$0.32−30% | −$0.27−53% | −$0.25 | −$0.26−24% | −$0.42+31% | −$0.40+48% | −$0.29+16% | −$0.12−54% | −$0.09−79% | −$0.16−60% | −$0.09−69% | |
| 8.8M+6% | 8.9M+6% | 8.9M+2% | 8.9M+1% | 8.9M+1% | 9.2M+3% | 11.1M+25% | 14M+57% | 16.8M+88% | 19.3M+111% | 19.3M+74% | 19.3M+38% |
EPS, diluted: 14 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY11 and Q4 FY12: share-days: the 12-month average less the 9-month, weighted by days. 12 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x10).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Marker Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MRKRMarker Therapeutics | $16M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Marker Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .